Complete disease clearance observed in 41 percent of patients with tapinarof cream 1 percent used once daily<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, July 13, 2022 (HealthDay News) — Four in 10 plaque psoriasis patients achieve complete disease clearance with tapinarof cream, 1 percent, according to a study published online June 26 in the Journal of the American Academy of Dermatology<\/em>.<\/p>\n Bruce Strober, M.D., Ph.D., from Yale University in New Haven, Connecticut, and colleagues assessed the long-term safety, efficacy, remittive effect, durability of response, and tolerability of tapinarof for the treatment of mild-to-severe plaque psoriasis. The analysis included 763 patients who completed the 12-week trial and were eligible for 40 weeks of open-label treatment and four weeks of follow-up.<\/p>\n The researchers found that 40.9 percent of patients achieved complete disease clearance (Physician Global Assessment [PGA] of 0). More than half of participants (58.2 percent) entering with PGA \u00e2\u0089\u00a52 achieved PGA of 0 or 1. For patients achieving PGA of 0, mean duration of remittive effect off-therapy was 130.1 days. No new safety signals were seen. Folliculitis (22.7 percent), contact dermatitis (5.5 percent), and upper respiratory tract infection (4.7 percent) were the most frequent adverse events.<\/p>\n “VTAMA [tapinarof] cream’s demonstrated combination of efficacy, remittive effect, durability, and tolerability make it a strong addition to the psoriasis armamentarium,” Philip M. Brown, M.D., J.D., chief medical officer of Dermavant Sciences, said in a statement.<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Dermavant, which manufactures tapinarof and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n